Hemodynamic Improvement Research Articles

Physiological arterial pressure improves renal performance during normothermic machine perfusion in a porcine kidney DCD model.

Normothermic machine perfusion (NMP) provides a platform for kidney quality assessment. Donation after circulatory death (DCD) donor kidneys are associated with great ischemic injury and high intrarenal resistance (IRR). This experimental study aims to investigate the impact of different perfusion pressures on marginal kidney function and injury during NMP. Twenty-seven slaughterhouse porcine kidneys were retrieved and subjected to 60min of warm ischemia time to mimic DCD condition. These kidneys were randomized into 75mmHg (subphysiological, n=9), 95mmHg (physiological, n=9), and 115mmHg NMP (high physiological, n=9). Renal function and injury were assessed during NMP. Three groups showed comparable IRR, with the 115mmHg group exhibiting the highest blood flow. The 95mmHg group [0.48 (0.36-1.15) ml/min/100g] and 115mmHg group [0.93 (0.45-1.41) ml/min/100g] showed significantly higher creatinine clearance compared to the 75mmHg group [0.16 (0.08-0.37) ml/min/100g] during the first hour of NMP (p=0.049, p=0.009, respectively). The 115mmHg group exhibited significantly higher oxygen consumption compared to the 75mmHg group at 30min of NMP [1.37 (1.05-1.92) versus 0.72 (0.61-0.82) mlO2/min/100g, p=0.009]. Perfusate neutrophil gelatinase-associated lipocalin (NGAL) levels were consistently lowest in the 95mmHg group and highest in the 75mmHg group. Aspartate aminotransferase (AST) levels of the 115mmHg group were significantly higher than the 75mmHg group. For kidneys with high IRR, both 95mmHg and 115mmHg perfusion pressures enable an early improvement in renal hemodynamics and function compared to 75mmHg during NMP, while a high physiological perfusion can cause additional injury.

Intravascular Ultrasound-Guided vs Angiography-Guided Drug-Coated Balloon Angioplasty in Patients With Complex Femoropopliteal Artery Disease.

Intravascular ultrasound (IVUS) guidance has been shown to yield favorable outcomes for endovascular treatment of femoropopliteal artery (FPA) disease with drug-coated balloon (DCB) angioplasty. However, the specific benefits of IVUS for treatment of complex FPA lesions remain uncertain. In this study, the authors compared the clinical impact of IVUS-guided vs angiography-guided DCB angioplasty in patients with complex or noncomplex FPA lesions. This study was a prespecified, primary subgroup analysis of the randomized IVUS-DCB trial. Patients with FPA undergoing DCB angioplasty were randomized to receive the procedure under IVUS or angiography guidance. The primary endpoint was 12-month primary patency; secondary endpoints included clinically driven target lesion revascularization (CD-TLR), sustained clinical improvement, and hemodynamic improvement. Among the 237 patients enrolled, 158 had complex FPA (Trans-Atlantic Inter-Society Consensus II [TASC II] type C/D), and 79 had noncomplex FPA (TASC II type A/B). In complex FPA, IVUS guidance was associated with significantly higher rates of primary patency (82.1% vs 60.3%; HR for loss of primary patency: 0.34; 95%CI: 0.16-0.70; P=0.002), freedom from CD-TLR (90.0% vs 76.9%; HR: 0.31; 95%CI: 0.13-0.75; P=0.01), and sustained clinical and hemodynamic improvement relative to angiography guidance. There was no significant difference in primary patency (87.5% vs 88.2%; HR: 1.84; 95%CI: 0.39-8.60; P=0.44) or occurrence secondary endpoints between the IVUS-guidance and angiography-guidance groups for patients with noncomplex FPA. In endovascular treatment of FPA using DCB, IVUS guidance was significantly associated with improved 12-month clinical outcomes, particularly in patients with complex FPA lesions.(Intravascular Ultrasound-Guided Drug-Coated Balloon Angioplasty for Femoropopliteal Artery Disease [IVUS-DCB] trial; NCT03517904).

Cerebral Hemodynamic Responses to Disease-Modifying and Curative Sickle Cell Disease Therapies.

Sickle cell disease (SCD) is a hemoglobinopathy resulting in hemoglobin-S production, hemolytic anemia, and elevated stroke risk. Treatments include oral hydroxyurea, blood transfusions, and hematopoietic stem cell transplantation (HSCT). Our objective was to evaluate the neurologic relevance of these therapies by characterizing how treatment-induced changes in hemoglobin (Hb) affect brain health biomarkers. In this interventional study, adults with and without SCD underwent a 3T-MRI at Vanderbilt University Medical Center at 2 time points before and after clinically indicated transfusion or HSCT or at 2 time points without the introduction of a new Hb-altering therapy (adult controls and patients with SCD on hydroxyurea). Cerebral blood flow (CBF; mL/100 g/min) and cerebral venous blood relaxation rate (s-1; a marker of Hb and blood oxygen content) responses were assessed to understand how these markers of brain health vary with Hb modulation. CBF was assessed with arterial spin labeling MRI, and blood relaxation rate was assessed using T2 relaxation under spin tagging MRI. Measures were pairwise compared within each cohort using a 2-tailed Wilcoxon signed-rank test, and regression was applied to evaluate the parameter and Hb change relationships. The significance criterion was 2-sided p < 0.05. Adults with (n = 43; age 28.7 ± 7.7 years; 42% male) and without (n = 13; age 33.5 ± 12.2 years; 46% male) SCD were evaluated. In adults receiving hydroxyurea (n = 10), neither Hb, CBF, nor venous relaxation rate changed between time 1 (Hb = 8.6 ± 1.2 g/dL) and time 2 (Hb = 9.0 ± 1.8 g/dL) (all p > 0.05). In transfusion patients (n = 19), Hb increased from 8.2 ± 1.4 g/dL to 9.3 ± 1.3 g/dL before vs after transfusion (p < 0.001), paralleling a CBF decrease of 14.2 mL/100 g/min (p < 0.001) toward control levels. The venous relaxation rate did not change after transfusion (p = 0.71). In HSCT patients (n = 14), Hb increased from 8.9 ± 1.9 g/dL to 12.9 ± 2.7 g/dL (p < 0.001) before vs after transplant, paralleling CBF decreases from 68.16 ± 20.24 to 47.43 ± 12.59 mL/100 g/min (p < 0.001) and increase in venous relaxation rate (p = 0.004). Across the Hb spectrum, a CBF decrease of 5.02 mL/100 g/min per g/dL increase in Hb was observed. Findings demonstrate improvement in cerebral hemodynamics after transfusion and transplant therapies compared with hydroxyurea therapy; quantitative relationships should provide a framework for using these measures as trial end points to assess how new SCD therapies affect brain health.

Pulmonary artery denervation by noninvasive stereotactic radiotherapy: a pilot study in swine models of pulmonary hypertension

Catheter-based pulmonary artery denervation (PADN) has achieved promising outcomes to treat pulmonary hypertension (PH). We herein present stereotactic body radiotherapy (SBRT) as a novel noninvasive approach for PADN. A single fraction of 15 Gy, 20 Gy or 25 Gy was delivered for PADN in a thromboxane A2 (TxA2) - induced acute PH swine model. We demonstrated that PADN by 20-Gy SBRT reduced mean pulmonary artery (PA) pressure during the TxA2 challenge. All SBRT dosages led to a deeper denervation area compared with radiofrequency ablation (RFA) and reduced sympathetic neural norepinephrine synthesis in the ablation zone. Probable radiation related side effects were mostly found in animals treated with 25-Gy. In subsequent monocrotaline-induced chronic PH animals, PADN by 20-Gy SBRT resulted in more significant improvement in pulmonary hemodynamics and PA remodeling in comparison to RFA. In summary, our findings suggest that appropriate SBRT scheme could balance the efficacy and safety for PADN, potentiating to be a novel strategy to treat PH.

Improvements in Hemodynamics and Right Heart Remodeling Following Balloon Pulmonary Angioplasty Treatment in Patients With Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Study.

Improvements in Hemodynamics and Right Heart Remodeling Following Balloon Pulmonary Angioplasty Treatment in Patients With Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Study.

Hemodynamic improvement in ARDS patients after VV ECMO implantation

Hemodynamic improvement in ARDS patients after VV ECMO implantation

A Case of Fat Embolism Syndrome Treated with Methylprednisolone.

A 74-year-old woman presented with sudden dyspnea 22 h after orthopedic surgery. Echocardiography revealed significant right ventricular dilatation, suggesting the development of acute pulmonary embolism. However, contrast computed tomography showed no signs of pulmonary thromboembolism, leading to suspicion of fat embolism syndrome (FES). Despite the administration of high-dose norepinephrine and dobutamine, her hemodynamic status did not improve, and high-dose methylprednisolone (250 mg) was administered. After administration, her hemodynamic status improved promptly, and she soon showed normotension. The current case suggests the possibility of high-dose methylprednisolone for hemodynamic improvement in FES.

PENILE HEMODYNAMIC RESPONSE TO PHOSPHODIESTERASE TYPE V INHIBITORS AFTER CAVERNOSAL SPARING INFLATABLE PENILE PROSTHESIS IMPLANTATION A PROSPECTIVE IMPLANTATION: A PROSPECTIVE RANDOMIZED OPEN-BLINDED END-POINT (PROBE) STUDY

Oral phosphodiesterase type V inhibitors (PDE5i), such as sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra), have become the first-line pharmacological treatment for most cases of ED. Objective: The main objective of the study is to find the penile hemodynamic response to phosphodiesterase type v inhibitors after cavernosal-sparing inflatable penile prosthesis implantation prospective implantation. Objective: To evaluate the penile hemodynamic response, erectile function, and patient satisfaction associated with PDE5i therapy after cavernosal sparing IPP implantation. Methods: This Prospective Randomized Open-Blinded End-Point (PROBE) was conducted at Mardan Medical Complex Peshawar from June 2024 to December 2024. Data were collected from 25 male patients. Patients underwent cavernosal sparing IPP implantation and were randomly assigned to two groups: Group A (n=13) received PDE5i postoperatively, while Group B (n=12) received a placebo. Hemodynamic measurements using Doppler ultrasound were conducted at baseline, 6 weeks post-surgery, and the 6-month follow-up. International Index of Erectile Function (IIEF) scores and patient satisfaction were also assessed. Results: Group A showed significant improvements in penile hemodynamics compared to Group B, with a higher peak systolic velocity (PSV: 38.7 ± 6.1 cm/s vs. 24.5 ± 5.3 cm/s), reduced end-diastolic velocity (EDV: 4.8 ± 2.3 cm/s vs. 8.9 ± 2.4 cm/s), and improved resistance index (RI: 0.88 ± 0.07 vs. 0.64 ± 0.09) at 6 months. Group A also reported higher IIEF scores and greater satisfaction with sexual function. Conclusions: Cavernosal sparing IPP implantation combined with PDE5i therapy significantly improves penile hemodynamics, erectile function, and patient satisfaction compared to IPP alone. This dual approach offers enhanced outcomes for managing severe ED.

10 tips on how to reduce iatrogenic AKI

Abstract Acute kidney injury (AKI) is a heterogeneous syndrome associated with worse clinical outcomes. Many treatments and procedures in the hospitalized patient can cause AKI. Hence, the incidence of iatrogenic AKI is expected to be high. In this review, we provide 10 practical tips on how to manage and avoid iatrogenic AKI. We cover identification of vulnerable patients by epidemiological data and recommend the usage of renal stress biomarkers for enhanced screening of high-risk patients. Further, we discuss the limitations of current diagnostic criteria of AKI. As a key takeaway, we suggest the implementation of novel damage biomarkers in clinical routine to identify subclinical AKI, which may guide novel clinical management pathways. To further reduce the incidence of procedure-associated AKI, we advocate for certain preventive measures. Foremost, this includes improvement of hemodynamics and avoidance of nephrotoxic drugs whenever possible. In cases of severe AKI, we provide tips for the implementation and management of renal replacement therapy and highlight the advantages of regional citrate anticoagulation. The furosemide stress test might be of help in recognizing patients who will require renal replacement therapy. Finally, we discuss the progression of AKI to acute and chronic kidney disease and management of this growing issue. Both can develop after episodes of AKI and have major implications for patient co-morbidity and long-term renal and non-renal outcomes. Hence, we recommend long-term monitoring of kidney parameters after AKI.

Harvi Cardiovascular Modeling Accurately Predicts Hemodynamic Improvements Produced by a New Direct Cardiac Compression Device.

Despite advancements in mechanical circulatory support (MCS) technology, persistent critical complications related to blood contact remain unresolved. To provide a safer alternative therapy, CorInnova is developing a non-blood contacting direct cardiac compression (DCC) device for MCS. To support product development toward clinical trials, a simulation platform has been developed to predict clinical outcomes under patient-specific conditions, guiding patient selection for clinical trials. The Harvi simulation was validated using preclinical in vivo data from experimental studies with the CorInnova device, with n = 28 hemodynamic samples simulated from animal data (n = 4 ovine). After confirming validation, further simulation was performed to predict additional hemodynamic outcomes not captured in animal studies. The simulated effects of CorInnova device therapy were not significantly different from animal data for cardiac output, systemic arterial blood pressure, mean pulmonary artery pressure, central venous pressure, or left ventricular pressure (p > 0.050). Harvi accurately predicts the effects of the CorInnova device in heart failure conditions and can be used in preparation for future clinical trials.

Abstract 4115531: Relationship between Ventricular Workload and Functional Response to Balloon Pulmonary Angioplasty (BPA) Therapy for Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Background: WHO functional classification (FC) is used to evaluate clinical response to BPA therapy and is associated with hemodynamic improvements in CTEPH patients. The relationships between FC and specific metrics of left and right ventricular workload during BPA remain unclear. Methods: CTEPH patients who underwent at least six BPA sessions and were included in the UCSD BPA registry were included for analysis. Left ventricular (LV) and right ventricular (RV) cardiac power output (CPO) and stroke work index (SWI) using thermodilution cardiac output were measured, along with FC, during each BPA session. BPA “responders” showed improved FC from III/IV at baseline to I/II after BPA therapy. BPA “non-responders” had unchanged FC III/IV symptoms before and after BPA therapy. ANOVA and Student T tests were used and P-value &lt;0.05 was significant. Results: A total of 66 subjects (55.5% female, BMI 28.3±6.10kg/m 2 ,16.7% prior pulmonary thromboendarterectomy surgery) were enrolled. Greater subject functionality by FC was significantly associated with higher LVCPO (class IV to I: 0.88±0.15, 0.94±0.28, 1.08±0.31, 0.95±0.27 watt; p&lt;0.001), higher LVSWI (29.4±6.6, 35.6±9.4, 40.8±8.8, 43.4±11.1 g*m/beat/m 2 ; p&lt;0.001), and lower RVCPO (0.37±0.10, 0.34±0.12, 0.34±0.14, 0.24±0.09 watt; p=0.003). RVSWI was not significantly associated with FC (14.8±3.7, 15.4±5.1, 15.1±5.0, 12.5±3.3 g*m/beat/m 2 ; p=0.075). Likewise, higher mean LVCPO (1.1±0.30 vs 0.93±0.27 watt; p&lt;0.001) and LVSWI (41.1±9.1 vs 35.2±9.4 g*m/beat/m 2 ; p&lt;0.001), but not RVCPO or RVSWI, were observed in subjects with FC I/II versus FC III/IV symptoms. BPA responders versus non-responders had higher overall LVCPO (1.01±0.27 vs 0.89±0.27 watt; p&lt;0.001) and LVSWI (39.0±8.9 vs 33.2±8.4 g*m/beat/m 2 ; p&lt;0.001), but not RVCPO (0.33±0.13 vs 0.34±0.13 watt; p=0.465) or RVSWI (15.2±4.8 vs 14.9±5.1 g*m/beat/m 2 ; p=0.694). Responders also had higher baseline LVSWI (p=0.029) and post-BPA LVSWI (p=0.028) compared to non-responders. Conclusions: CTEPH patient functionality and symptoms during BPA therapy are associated with metrics of left and right ventricular workload. Patients with more severe FC III/IV symptoms produce lower LV workload. Treatment responders with improved FC after BPA therapy achieve higher overall, pre-BPA, and post-BPA LV workload. Specific metrics of ventricular workload may be helpful determinants of CTEPH patient symptoms and BPA treatment response.

Three-Year Clinical and Hemodynamic Evaluation of the Hydra Self-Expanding Transcatheter Aortic Valve in Patients With Severe Aortic Stenosis.

The Hydra CE study revealed 1-year favorable efficacy of TAVR, showing a large effective orifice area (EOA), low gradient, and acceptable complication rates. We evaluated the 3-year clinical and hemodynamic outcomes of Hydra self-expanding transcatheter aortic valve (manufactured by Vascular Innovations Co Ltd, Nonthaburi, Thailand; a subsidiary of Sahajanand Medical Technologies Limited, India) in patients with symptomatic severe aortic stenosis at high or extremely high surgical risk. The Hydra CE study was a prospective, multicenter, single-arm study. A total of 157 patients were enrolled in the study, out of whom 54 patients from two centers (Lithuania and Poland) had provided consent for long-term follow-up at recruitment, with a planned 5-year follow-up period. The primary endpoint was all-cause mortality, and patients were followed up for up to 3 years, with an assessment of clinical and echocardiographic outcomes. Among the 54 patients, the average age was 81.0 ± 4.1 years. The mean STS score was 3.2 ± 2.0%. At 3 years, all-cause mortality had occurred in 14.8% of patients, including 3.7% cardiovascular deaths and 1.9% device-related deaths. There was a progressive enhancement in EOA that is, 0.68 ± 0.15 cm2 at baseline to 1.97 ± 0.52 cm2 at 3 years (p < 0.001) as well as significant improvement in the mean aortic valve gradient that is, 53.4 ± 14.24 mmHg at baseline to 8.6 ± 2.80 mmHg at 3 years (p < 0.001). New permanent pacemaker implantation rates up to 3-year follow-up was 12.9%. The 3-year results of the Hydra CE study demonstrated consistent improvements in hemodynamics over time. The study also revealed favorable safety and efficacy trends, along with low occurrences of new permanent pacemaker implantations and paravalvular leaks.

Exercise Training in Patients With Hypertrophic Cardiomyopathy Without Left Ventricular Outflow Tract Obstruction: A Randomized Clinical Trial.

Patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction commonly experience reduced exercise capacity. Physical training improves exercise capacity in these patients, but whether the underlying effects of exercise are a result of central hemodynamic or peripheral improvement is unclear. This study assessed whether exercise training reduces left ventricular filling pressure measured during exercise in patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction. Between March 2019 and June 2022, patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction were randomly assigned (1:1) to a 12-week (3 h/wk) supervised, moderate-intensity exercise training program or continued usual activity. The primary outcome was the change in invasively measured pulmonary capillary wedge pressure during mild exercise (25 W) from baseline to week 12. Pressure tracings were analyzed offline by a blinded investigator. Secondary outcomes included changes in peak oxygen consumption, cardiac index, quality of life, echocardiographic indices of diastolic function, and natriuretic peptides. Of 59 patients randomized (mean age, 58.1±12.2 years; 27% women), 51 (86%) completed all follow-up assessments. At week 12, the change in 25-W pulmonary capillary wedge pressure was -2.8±6.8 mm Hg in the exercise group, compared with +1.2±4.9 mm Hg in the usual-activity group (between-group difference, 4.0 mm Hg [95% CI, 0.7-7.3]; P=0.018). Peak oxygen consumption improved by +1.8±2.0 mL/kg/min in the exercise group versus -0.3±3.1 mL/kg/min in the usual-activity group (P=0.005). Exercise training improved the ventilatory efficiency (VE/VCO2) slope compared with usual activity (between-group difference, 2.0 [95% CI, 0.6-3.5]; P=0.006). Peak cardiac index improved by +0.38±1.38 L/min/m2 in exercise versus -0.85±1.20 L/min/m2 in the usual-activity group (P=0.002). Change in overall Kansas City Cardiomyopathy Questionnaire score was similar between groups. However, the change in physical limitation scores (+8.4±12.0 points in exercise versus +0.7±6.8 points in usual-activity group; P=0.034) and quality-of-life scores (+8.7±18.0 points in exercise versus 0.7±4.0 points in usual-activity group; P=0.01) differed significantly. There were no significant changes in diastolic function assessed by echocardiography or in natriuretic peptides. In patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction, a 12-week moderate-intensity exercise training program resulted in reduced left ventricular filling pressures at mild exertion and improved exercise performance. URL: https://www.clinicaltrials.gov; Unique identifier: NCT03537183.

Advancing Heart Failure Treatment: The Role of Multipoint Pacing in Cardiac Resynchronization Therapy

Cardiac resynchronization therapy (CRT) with biventricular pacing is a standard therapy for patients with heart failure, reduced ejection fraction, and electrical dyssynchrony. However, approximately 30% of patients do not respond to CRT. Multipoint pacing (MPP) has emerged as an innovative strategy that paces multiple left ventricular sites to achieve more comprehensive resynchronization. This review explores the evolution of MPP, including the underlying scientific rationale, clinical evidence from key trials, technological considerations of quadripolar leads and programmability, patient selection criteria, optimization strategies, and future directions. Early feasibility studies demonstrated acute hemodynamic improvements with MPP. Larger trials have shown superior outcomes with MPP compared to conventional biventricular pacing, including increased CRT response rates, reduced hospitalizations, and improved ejection fraction and reverse remodeling. However, recent multicenter trials found no significant differences between the population's MPP and biventricular pacing. Ongoing research aims to refine patient selection for MPP and optimize lead positioning and programming configurations to maximize benefits. As technological capabilities expand, MPP promises to provide tailored, physiological pacing therapies that may enhance outcomes for heart failure patients requiring CRT. This comprehensive review examines the various aspects of MPP, including its scientific foundation, clinical evidence, technological considerations, impact on patient quality of life, and future implications. By critically assessing the current literature and identifying gaps in knowledge, we aim to provide a thorough understanding of MPP’s role in the evolving landscape of heart failure management.

Improvements in Hemodynamics and Right Heart Remodeling Following Balloon Pulmonary Angioplasty Treatment in Patients With Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Study.

This study aimed to evaluate the hemodynamic alterations and right heart remodeling dynamics in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) undergoing treatment with balloon pulmonary angioplasty (BPA). This retrospective cohort study involved a cohort of 31 patients with a confirmed diagnosis of CTEPH. Comprehensive clinical evaluations were systematically performed before BPA, and at 3 and 6 months following the procedure. Significant clinical progress was evidenced by the uplift in the percentage of patients achieving WHO-FC II, escalating from 19.35% at baseline to 51.61% at 6 months after BPA (p = 0.003). NT-proBNP levels significantly dropped from a median of 614.6 to 69.9 pg/mL(p < 0.001). Hemodynamic assessments showed significant decreases in mean PAP from 45.53 ± 11.19 to 22.56 ± 5.81 mmHg (p < 0.001) and PVR from 8.33 to 2.86 WU (p < 0.001). Echocardiographic analysis revealed substantial reductions in the right atrial area (RAA, from 20.29 ± 7.55 to 16.79 ± 4.82 cm2, p < 0.001) and right ventricular internal diameter (RVID, from 4.13 ± 0.79 to 3.68 ± 0.59 cm, p = 0.001) at the 3-month interval post-BPA. These improvements were sustained or even enhanced by the 6-month mark, with RAA and RVID further diminishing (to 14.46 ± 3.78 cm2 and 3.29 ± 0.54 cm, respectively; both p < 0.01). The TAPSE/PASP ratios showed progressive improvement from baseline (0.32 ± 0.13) to 3 months (0.42 ± 0.13) and continued to improve at 6 months following BPA (0.50 ± 0.11, p = 0.04 compared to 3 months post-BPA). BPA has significantly ameliorated clinical conditions, hemodynamic profiles, and initiated a continued reversal in right heart remodeling in patients with CTEPH.

Assessment of hemodynamic parameters and caudal vena cava-to-aorta ratio pre- and post-pericardiocentesis in dogs with cardiac tamponade.

To evaluate haemodynamic parameters and ultrasonographic measurements of the caudal vena-cava-to-aorta ratio at the splenorenal view in canine cardiac tamponade before and 30 minutes after pericardiocentesis. Dogs presenting with cardiac tamponade at two veterinary hospitals were included. Triage examination, noninvasive systolic arterial blood pressure, shock index, venous lactatemia and POCUS results were recorded at admission and 30 minutes after pericardiocentesis. This prospective observational study included 22 dogs, and all had an increased caudal vena-cava-to-aorta ratio. After pericardiocentesis, there were significant changes in vital signs, including a decrease in the median heart rate by 42.1%, a decrease in the median respiratory rate by 40.1%, and an increase in the median rectal temperature from 37.8°C (range: 35.6 to 39.2) to 38.1°C ( 36.1 to 38.7). In regards of hemodynamic parameters, the median systolic arterial pressure increased significantly by 23.2%, the shock index decreased significantly by 52.8%, the median lactate level decreased significantly from 6.1 mmol/L (1.4 to 14.7) to 3.6 mmol/L (1.1 to 13.6), and the median caudal vena-cava-to-aorta ratio decreased significantly by 37.5%, from 1.76 (1.35 to 2.13) to 1.12 (0.91 to 1.51). This study demonstrated an increased caudal vena-cava-to-aorta ratio in dogs with cardiac tamponade and a rapid haemodynamic improvement in dogs with cardiac tamponade within 30 minutes of the pericardiocentesis, resulting in excellent short-term prognosis.

Endarterectomy in CTEPH: hemodynamic improvement and RV-PA coupling

Abstract Introduction Pulmonary artery endarterectomy (PAE) remains the gold standard in treating chronic thromboembolic pulmonary hypertension (CTEPH). Reducing the thrombotic burden and mechanical obstruction of the pulmonary artery (PA) leads to significant hemodynamic improvement, allowing for favorable right ventricular (RV) remodeling. Methods Single center retrospective study, including 30 pts submitted to PEA over a 7-year period. Hemodynamic assessment was performed by right heart catheterization (RHC) before PEA, immediately after and at 6-month follow-up (FUP). Echocardiographic assessment of RV function was acquired at baseline and 6m FUP. Mean absolute differences were calculated before and after PEA. Differences between groups were assessed with ANOVA analysis and ROC curve analysis allowed us to define a cut-off point in mPAP reduction to predict favorable RV remodeling. Results We included 30 pts with a mean age of 57,9 ± 13 years old and slight predominance of female sex (57%). Regarding risk assessment with the 4 strata tool at baseline, 23% of pts were high risk, 20% intermediate high, 27% intermediate low and 6% at low risk. Pulmonary hemodynamics improved immediately after PEA, as indicated by a mean reduction of 28,3 ±17 mmHg in mPAP; 44,4±27,6mmHg in sPAP; 8±3,4 Wu in PVR and an increase in CO of 0,5±1 l/min. This improvement was sustained at 6-m post PEA assessment, with a mean reduction of 31,5 ±26,7 mmHg in mPAP; 48,3±41,2mmHg in sPAP; 6,3±6,2Wu in PVR and a 0,5±1 l/min increase in CO. Regarding RV remodeling at 6m post PEA, an increase of 0.15±0.2mm/mmHg in TAPSE/PSAP ratio and 3±2,8cm/s in Tricuspid S’ were recorded. RV/PA uncoupling, defined as TAPSE/PSAP &amp;lt;0,31 mm/mmHg, was evident in 73% of pts at baseline, 25% of which recovered at 6m follow-up. There were no significant differences between groups, according to the 4 strata risk assessment at baseline, regarding pulmonary hemodynamics and RV remodeling. Through ROC curve analysis, we were able to define a cut-off point of 37mmHg in immediate mPAP post-op reduction to predict RV-RA coupling normalization at 6-m FUP (sensitivity 70%, specificity 89%). Conclusions PEA remains a cornerstone of CTEPH treatment. It’s impact on improving pulmonary hemodynamics is immediate and maintained at 6-month FUP. This improvement may be expected regardless of risk assessment at baseline. Reducing RV afterload allows favorable remodeling and an immediate post operative reduction of mPAP &amp;gt; 37mmHg may predict normalization of RV-PA coupling.

Impact of SAPIEN3 Ultra RESILIA on improvement of valve performance: Insights from the multicenter registry: a propensity-score matched analysis

Abstract Backgrounds: Transcatheter aortic valve implantation (TAVI) is now a cornerstone treatment for symptomatic severe aortic stenosis across all risk profiles, including low-risk and younger patients. As such, the performance and durability of transcatheter heart valves (THVs) are paramount. SAPIEN3 Ultra RESILIA (S3 UR) is expected to improve hemodynamics compared with SAPIEN3 (S3) due to the use of RESILIA bovine pericardial tissue and modified sawing maneuvers for each of three leaflets in 20 and 23mm valves. Aim The aim of study was to evaluate the hemodynamic improvement with S3 UR compared to S3 who underwent TAVI. Methods In a multicenter TAVI registry, we identified 1,931 patients who received a balloon-expandable valve over the past three years. We focused on post-procedural effective orifice area (EOA), post-procedural indexed EOA (EOAi), incidence of prosthesis-patient mismatch (PPM), paravalvular leakage (PVL) and post-procedural mean pressure gradient (mean PG) as our primary endpoints. We preformed propensity score matching analysis using a 1:1 ratio. Parameters including aortic stenosis severity, % oversizing and post dilatation were incorporated into the matching model. Results Of patients, mean age was 84 years old and 37.9% were male. EOAi was significantly larger in S3 UR group than in the S3 group for both cohorts [overall cohort: 1.21 (1.02 – 1.36) vs. 1.08 (0.93 – 1.26), P = 0.001; propensity matched cohort: 1.21 (1.01 – 1.35) vs. 1.11 (0.91 – 1.27), p = 0.042, respectively] (Figure 1). Similarly, the degree of PVL was significantly less in the S3 UR group than in the S3 group for both cohorts. In the propensity matched cohort, mild PVL was identified in 6.5% vs. 14.7%, and moderate PVL was present in 0.0% vs. 1.6% (p = 0.028). Peak PG and mean PG were significantly lower in the S3 UR group than in the S3 group for both cohorts. In the propensity matched cohort, peak PG was 17.7 (14.3 – 24.5) vs. 23.2 (18.2 – 29.2) (p = 0.001) and mean PG was 9.0 (7.1 – 12.5) vs. 11.5 (8.9 -14.8) (p = 0.005), respectively. The incidence of PVL ≥ mild, mean PG ≥ 20 mmHg, moderate PPM and severe PPM were tend to be lower in S3 UR group than in the S3 group for both cohorts (Figure 2). Conclusion The S3 UR valve exhibits significant hemodynamic improvements compared to the S3 valve, underscoring its potential for improved clinical outcomes in TAVI patients.

Acute vasoreactivity testing for severe pulmonary hypertension associated with lung disease

Abstract Background Pulmonary hypertension results in clinical deterioration and increases mortality risk in patients with lung disease (LD), including chronic obstructive pulmonary disease, interstitial lung disease and combined pulmonary fibrosis and emphysema. Though acute vasoreactivity testing predicts long term-survival of patients with pulmonary arterial hypertension (PAH), its clinical impact for patients with pulmonary hypertension associated with LD (LD-PH) remains unknown. Purpose The purpose of this study is to clarify the clinical impact of acute vasoreactivity testing using inhaled nitric oxide for severe LD-PH. Methods We retrospectively reviewed 65 consecutive patients with LD-PH between January 2014 and December 2022; 48 patients (73 [68–78] years; males, 81%; median follow-up period 23 [7–35] months) with severe pulmonary hypertension who underwent acute vasoreactivity testing were included. We divided the patients based on a median pulmonary vascular resistance (PVR) response (−15%) in acute vasoreactivity testing into the high-responder (PVR response ≦−15%) and the low-responder (PVR response &amp;gt;−15%) groups. Results Acute vasoreactivity testing significantly decreased mean pulmonary arterial pressure (mPAP) (from 41 [34–48] to 36 [31–40] mmHg, P&amp;lt;0.01) and PVR (from 10.7 [8.3–13.8] to 8.9 [6.6–11.4] Wood units, P&amp;lt;0.01). The high-responder group had better long-term survival than the low-responder group (P = 0.03). Univariate Cox regression analysis showed that the prognostic factors for better survival included younger age, high-responder to acute vasoreactivity testing, and PAH-specific therapy (P &amp;lt;0.01, 0.04, 0.03, respectively). There were correlations between the PVR response at acute vasoreactivity testing and improvement in mPAP (R=0.40, P=0.03) or PVR (R = 0.47, P &amp;lt;0.01) with PAH-specific therapy. Conclusions PVR response at acute vasoreactivity testing was associated with better long-term survival and haemodynamic improvement with PAH-specific therapy. Acute vasoreactivity testing may be useful to predict the responders to PAH-specific therapy and long-term survival in patients with severe LD-PH.

MELHORES ELEIÇÕES PARA DIAGNÓSTICO E TRATAMENTO DA HIPERTENSÃO PULMONAR ASSOCIADA A DOENÇA CARDÍACA ESQUERDA

Pulmonary hypertension associated with left heart disease (PH-LHD) is the most prevalent form of pulmonary hypertension, affecting patients with heart failure and valvular disease. Divided into isolated post-capillary and combined pre-capillary, PH-LHD is characterized by a challenging prognosis, due to the difficulty in identifying the factors that contribute to its progression. Early diagnosis is essential and can be aided by imaging tests and procedures such as cardiac catheterization, with volume testing being an important tool to differentiate the types of PH. The management of PH-LHD involves symptom control and treatment of the underlying heart failure. Although there are no specific therapies to significantly improve the prognosis, diuretics and selective pulmonary vasodilators are used, with surgical interventions in more severe cases. Recent research has investigated treatments such as phosphodiesterase-5 inhibitors, which have shown some hemodynamic improvement, and pulmonary artery denervation, a promising technique, but still in the investigational phase. Despite advances, PH-DCE remains associated with high mortality, especially in patients with progressive elevation of pulmonary vascular resistance. Treatment should focus on managing underlying cardiac diseases and seeking new therapeutic approaches.